Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 induction study of vixarelimab in moderate to severe ulcerative colitis
MOH_2024-03-19_013324Phase 2Not yet recruiting
- Sponsor
- Genentech
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of vixarelimab in autoimmune colitis (3 arms), sponsored by Genentech. Primary endpoints: Induction efficacy of vixarelimab versus placebo and Induction efficacy in advanced-therapy failure subgroup. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
vixarelimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2024-03-19_013324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-19_013324.